Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes

Angelo Antonini, Ashley Yegin, Cornelia Preda, Lars Bergmann, Werner Poewe

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p

Original languageEnglish
Pages (from-to)231-235
Number of pages5
JournalParkinsonism and Related Disorders
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Keywords

  • Advanced Parkinson's disease
  • Duodenal levodopa-carbidopa infusion
  • Motor symptoms
  • Non-motor symptoms
  • Quality of life
  • Routine patient care

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes'. Together they form a unique fingerprint.

Cite this